Australia's most trusted source of pharma news
Thursday, 19 September 2019
Lost Your Access?
Where GPs are at in 2019
Patients' reasons for visiting are changing.
Once-a-day pill for HIV
TGA success for ViiV after PBAC 'minded to recommend'.
Meet Novartis' hands-on Dad
Parents speak after leave policy update takes effect.
First joint cross-border approval
Aust, US, Canada greenlight cancer therapy under Project Orbis.
Bayer tops digital presence
But pharma scores relatively low across the board.
New top team at Bayer
Specialty medicines division leadership team in formation.
Bankruptcy filing clouds Mundi
Owners expected to sell as court settlement moves forward.
Will Mylan go direct now?
Not out of the question with Pfizer in charge analyst says.
AbbVie/Allergan merger protest
Groups ask US fair trade body to disallow deal.
More MA contenders emerge
Some who were 'considering' will now run for board.
J&J meets Hunt, Bowen
Senior politicians attend Canberra event.
More fuel for biosim uptake
Consortium given $8m+ for rheumatology script program.
Rebates must stay says MA
'Critical for ongoing access,' CEO Liz de Somer maintains.
Executive step trips females
Figures show drop out between management levels.
Lundbeck eyes migraine market
New drug on horizon with CGRP class expecting more patients.
Top of the Hill
Supply chain reform in limbo
No timetable, no legislation and impetus fading.
Amgen, GSK drugs copied
Sandoz and Alphapharm add options.
Novartis' NSCLC breakthrough
Could become first targeted drug against mutated form.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design